Min Kyung Kim

Min Kyung Kim

Auto-generated profile, based on publicly available information

Min Kyung Kim

Department of Cell and Developmental Biology, BK21 Program and Dental Research Institute (DRI), School of Dentistry, Seoul National University, Seoul 03080, Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2022 in Molecules and Cells
Verified
Journal Article
Open access
PDF file
SHSeo Jin Hong
Seo Jin Hong
SJSuhan Jung
Suhan Jung
JJJi Sun Jang
Ji Sun Jang
SMShenzheng Mo
Shenzheng Mo
JKJun-Oh Kwon
Jun-Oh Kwon
HKHong-Hee Kim
Hong-Hee Kim
Seo Jin Hong, Suhan Jung, Ji Sun Jang, Shenzheng Mo, Jun-Oh Kwon, Min Kyung Kim, and Hong-Hee Kim*. Mol. Cells 2022;45:749-60. https://doi.org/10.14348/molcells.2022.0058

1 November 2019 in Molecules and Cells
Verified
Journal Article
Open access
MKMin Kyung Kim
Min Kyung Kim
BKBongjun Kim
Bongjun Kim
JKJun-Oh Kwon
Jun-Oh Kwon
MSMin-Kyoung Song
Min-Kyoung Song
SJSuhan Jung
Suhan Jung
HKHong-Hee Kim
Hong-Hee Kim
For physiological or pathological understanding of bone disease caused by abnormal behavior of osteoclasts (OCs), functional studies of molecules that regulate the generation and action of OCs are required. In a microarray approach, we found the suppression of tumorigenicity 5 (ST5) gene is upregulated by receptor activator of nuclear factor-κB ligand (RANKL), the OC differentiation factor. Although the roles of ST5 in cancer and β-cells have been reported, the function of ST5 in bone cells has not yet been investigated. Knockdown of ST5 by siRNA reduced OC differentiation from primary precursors. Moreover, ST5 downregulation decreased expression of NFATc1, a key transcription factor for osteoclastogenesis. In contrast, overexpression of ST5 resulted in the opposite phenotype of ST5 knockdown. In immunocytochemistry experiments, the ST5 protein is colocalized with Src in RANKL-committed cells. In addition, ST5 enhanced activation of Src and Syk, a Src substrate, in response to RANKL. ST5 reduction caused a decrease in RANKL-evoked calcium oscillation and inhibited translocation of NFATc1 into the nucleus. Taken together, these findings provide the first evidence of ST5 involvement in positive regulation of osteoclastogenesis via Src/Syk/calcium signaling.

30 November 2021 in Journal of Bone Metabolism
Verified
Journal Article
Open access
PDF file
MSMin-Kyoung Song
Min-Kyoung Song
SJSuhan Jung
Suhan Jung
SHSeojin Hong
Seojin Hong
JKJun-Oh Kwon
Jun-Oh Kwon
MKMin Kyung Kim
Min Kyung Kim
HKHong-Hee Kim
Hong-Hee Kim
Background: Protein methylation has important role in regulating diverse cellular responses, including differentiation, by affecting protein activity, stability, and interactions. AZ505 is an inhibitor of the SET and MYND domain-containing protein 2 lysine methylase. In this study, we investigated the effect of AZ505 on osteoblast and osteoclast differentiation in vitro and evaluated the effect of AZ505 in vivo on the long bones in mice.Methods: Osteoblast differentiation was assessed by alkaline phosphatase (ALP) and Alizarin red staining after culturing calvarial preosteoblasts in an osteogenic medium. Osteoclast differentiation was analyzed by tartrate-resistant acid phosphatase (TRAP) staining in bone marrow-derived macrophages cultured with macrophage-colony stimulating factor and receptor activator of nuclear factor-κB ligand (RANKL). For in vivo experiments, mice were intraperitoneally injected with AZ505 and femurs were examined by micro-computed tomography.Results: AZ505 increased ALP and Alizarin red staining in cultured osteoblasts and the expression of osteoblast marker genes, including Runx2 and osteocalcin. AZ505 resulted in decreased TRAP-staining of osteoclasts and expression of c-Fos and nuclear factor of activated T cells transcription factors and osteoclast marker genes, including cathepsin K and dendritic cell-specific transmembrane protein. Unexpectedly, in vivo administration of AZ505 markedly decreased the trabecular bone mass of femurs. In support of this catabolic result, AZ505 strongly upregulated RANKL expression in osteoblasts.Conclusions: The results indicate that AZ505 has a catabolic effect on bone metabolism in vivo despite its anabolic effect in bone cell cultures. The findings indicate that cell culture data should be extrapolated cautiously to in vivo outcomes for studying bone metabolism.